- Home
- AMS vs AFMD Comparison
AMS vs AFMD Comparison
Compare AMS & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- AFMD
- Stock Information
- Founded
- AMS 1980
- AFMD 2000
- Country
- AMS United States
- AFMD Germany
- Employees
- AMS N/A
- AFMD N/A
- Industry
- AMS Medical Specialities
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- AFMD Health Care
- Exchange
- AMS Nasdaq
- AFMD Nasdaq
- Market Cap
- AMS 21.1M
- AFMD 17.5M
- IPO Year
- AMS N/A
- AFMD 2014
- Fundamental
- Price
- AMS $3.22
- AFMD $1.15
- Analyst Decision
- AMS
- AFMD Strong Buy
- Analyst Count
- AMS 0
- AFMD 5
- Target Price
- AMS N/A
- AFMD $13.50
- AVG Volume (30 Days)
- AMS 12.4K
- AFMD 363.4K
- Earning Date
- AMS 11-13-2024
- AFMD 11-14-2024
- Dividend Yield
- AMS N/A
- AFMD N/A
- EPS Growth
- AMS 779.12
- AFMD N/A
- EPS
- AMS 0.61
- AFMD N/A
- Revenue
- AMS $24,969,000.00
- AFMD $6,287,085.00
- Revenue This Year
- AMS $27.74
- AFMD N/A
- Revenue Next Year
- AMS $17.72
- AFMD $212.48
- P/E Ratio
- AMS $5.30
- AFMD N/A
- Revenue Growth
- AMS 20.83
- AFMD N/A
- 52 Week Low
- AMS $2.51
- AFMD $1.03
- 52 Week High
- AMS $4.60
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- AMS 52.61
- AFMD 28.57
- Support Level
- AMS $3.03
- AFMD $1.03
- Resistance Level
- AMS $3.14
- AFMD $1.41
- Average True Range (ATR)
- AMS 0.13
- AFMD 0.11
- MACD
- AMS 0.00
- AFMD 0.05
- Stochastic Oscillator
- AMS 52.78
- AFMD 23.53
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.